CN105142649A - 造影剂配制品与有关制备方法 - Google Patents

造影剂配制品与有关制备方法 Download PDF

Info

Publication number
CN105142649A
CN105142649A CN201480022899.5A CN201480022899A CN105142649A CN 105142649 A CN105142649 A CN 105142649A CN 201480022899 A CN201480022899 A CN 201480022899A CN 105142649 A CN105142649 A CN 105142649A
Authority
CN
China
Prior art keywords
complex
composition
formula
mol
dota
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480022899.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·梅迪纳
M·萨巴图
A·珀蒂
M·波尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48856855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105142649(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guerbet SA filed Critical Guerbet SA
Priority to CN202211543013.4A priority Critical patent/CN116173247A/zh
Publication of CN105142649A publication Critical patent/CN105142649A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
CN201480022899.5A 2013-04-26 2014-04-28 造影剂配制品与有关制备方法 Pending CN105142649A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211543013.4A CN116173247A (zh) 2013-04-26 2014-04-28 造影剂配制品与有关制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1353883 2013-04-26
FR1353883 2013-04-26
PCT/EP2014/058617 WO2014174120A1 (fr) 2013-04-26 2014-04-28 Formulation de produit de contraste et son procede de preparation associe

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211543013.4A Division CN116173247A (zh) 2013-04-26 2014-04-28 造影剂配制品与有关制备方法

Publications (1)

Publication Number Publication Date
CN105142649A true CN105142649A (zh) 2015-12-09

Family

ID=48856855

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480022899.5A Pending CN105142649A (zh) 2013-04-26 2014-04-28 造影剂配制品与有关制备方法
CN202211543013.4A Pending CN116173247A (zh) 2013-04-26 2014-04-28 造影剂配制品与有关制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211543013.4A Pending CN116173247A (zh) 2013-04-26 2014-04-28 造影剂配制品与有关制备方法

Country Status (14)

Country Link
US (1) US10918743B2 (enExample)
EP (1) EP2988756B2 (enExample)
JP (1) JP6608805B2 (enExample)
KR (1) KR102231121B1 (enExample)
CN (2) CN105142649A (enExample)
BR (1) BR112015026473B1 (enExample)
CA (1) CA2909919C (enExample)
DK (1) DK2988756T4 (enExample)
ES (1) ES2626582T5 (enExample)
HR (1) HRP20170874T4 (enExample)
HU (1) HUE033219T2 (enExample)
PL (1) PL2988756T5 (enExample)
PT (1) PT2988756T (enExample)
WO (1) WO2014174120A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110290815A (zh) * 2016-12-21 2019-09-27 通用电气医疗集团股份有限公司 适合作为mri显像剂的基于四氮杂双环-大环的锰螯合化合物
CN113646308A (zh) * 2019-01-17 2021-11-12 法国加栢 钆和基于非对映异构体富集的pcta的螯合配体的络合物及其制备和纯化方法
CN113646309A (zh) * 2019-01-17 2021-11-12 法国加栢 钆和基于pcta的螯合配体的非对映异构体富集的络合物和合成方法
CN116209661A (zh) * 2020-07-17 2023-06-02 法国加栢 用于制备基于pcta的螯合配体的方法
US11884686B2 (en) 2016-06-20 2024-01-30 Ge Healthcare As Chelate compounds

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
WO2019122255A1 (en) 2017-12-20 2019-06-27 General Electric Company Anionic chelate compounds
KR102815156B1 (ko) 2018-08-06 2025-05-30 브라코 이미징 에스.피.에이. 가돌리늄 함유 pcta-기반 조영제
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
WO2022269618A1 (en) 2021-06-25 2022-12-29 Beacon Mri Ltd Particles for use in hyperpolarization

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876695A (en) * 1986-11-28 1999-03-02 Schering Aktiengesellschaft Metal complex-containing pharmaceutical agents
CN101305006A (zh) * 2005-10-07 2008-11-12 加柏公司 含有短氨基醇链的化合物和用于医学成像的金属络合物
CN101977633A (zh) * 2008-02-19 2011-02-16 法国加柏公司 用于制备对比剂的药物配制品的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
EP0367787B2 (en) * 1987-06-30 1999-01-27 Mallinckrodt, Inc. (a Delaware corporation) Method for enhancing the safety of metal-ligand chelates as x-ray contrast agents
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
GB9001245D0 (en) * 1990-01-19 1990-03-21 Salutar Inc Compounds
CA2039399C (en) * 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
ATE192047T1 (de) 1991-12-10 2000-05-15 Dow Chemical Co Bicylclische, polyazamakrocyclocarbonsäure- komplexe, konjugate, herstellung und verwendung als kontraststoffe
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
DE19719033C1 (de) 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6559330B1 (en) 1999-09-09 2003-05-06 Schering Aktiengesellschaft Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
FR2927539B1 (fr) * 2008-02-19 2010-07-30 Guerbet Sa Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
EP2554167A1 (en) * 2011-08-02 2013-02-06 Bracco Imaging S.p.A New use of l-histidine and derivatives thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876695A (en) * 1986-11-28 1999-03-02 Schering Aktiengesellschaft Metal complex-containing pharmaceutical agents
CN101305006A (zh) * 2005-10-07 2008-11-12 加柏公司 含有短氨基醇链的化合物和用于医学成像的金属络合物
CN101977633A (zh) * 2008-02-19 2011-02-16 法国加柏公司 用于制备对比剂的药物配制品的方法

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884686B2 (en) 2016-06-20 2024-01-30 Ge Healthcare As Chelate compounds
CN110290815A (zh) * 2016-12-21 2019-09-27 通用电气医疗集团股份有限公司 适合作为mri显像剂的基于四氮杂双环-大环的锰螯合化合物
CN113646308A (zh) * 2019-01-17 2021-11-12 法国加栢 钆和基于非对映异构体富集的pcta的螯合配体的络合物及其制备和纯化方法
CN113646309A (zh) * 2019-01-17 2021-11-12 法国加栢 钆和基于pcta的螯合配体的非对映异构体富集的络合物和合成方法
CN113698400A (zh) * 2019-01-17 2021-11-26 法国加栢 钆和基于pcta的螯合配体的非对映异构体富集的络合物和合成方法
CN113735854A (zh) * 2019-01-17 2021-12-03 法国加栢 钆和基于非对映异构体富集的pcta的螯合配体的络合物及其制备和纯化方法
TWI811518B (zh) * 2019-01-17 2023-08-11 法商加柏公司 釓和基於ｐｃｔａ的螯合配位基的非鏡像異構物富集的錯合物及其製備和純化方法
TWI812832B (zh) * 2019-01-17 2023-08-21 法商加柏公司 釓和基於pcta的螯合配位基的非鏡像異構物富集的錯合物和合成方法
CN113735854B (zh) * 2019-01-17 2024-05-14 法国加栢 钆和基于非对映异构体富集的pcta的螯合配体的络合物及其制备和纯化方法
CN116209661A (zh) * 2020-07-17 2023-06-02 法国加栢 用于制备基于pcta的螯合配体的方法

Also Published As

Publication number Publication date
JP6608805B2 (ja) 2019-11-20
HUE033219T2 (en) 2017-11-28
BR112015026473A2 (pt) 2017-07-25
ES2626582T3 (es) 2017-07-25
DK2988756T3 (en) 2017-06-26
EP2988756B1 (fr) 2017-03-08
BR112015026473B1 (pt) 2020-12-01
ES2626582T5 (es) 2022-10-07
US10918743B2 (en) 2021-02-16
PT2988756T (pt) 2017-05-08
DK2988756T4 (da) 2022-08-08
KR102231121B1 (ko) 2021-03-23
EP2988756B2 (fr) 2022-05-18
HRP20170874T4 (hr) 2022-09-02
KR20160002821A (ko) 2016-01-08
CN116173247A (zh) 2023-05-30
US20160101196A1 (en) 2016-04-14
JP2016521275A (ja) 2016-07-21
PL2988756T5 (pl) 2022-09-26
CA2909919A1 (fr) 2014-10-30
CA2909919C (fr) 2022-07-12
EP2988756A1 (fr) 2016-03-02
PL2988756T3 (pl) 2017-08-31
HRP20170874T1 (hr) 2017-09-22
WO2014174120A1 (fr) 2014-10-30

Similar Documents

Publication Publication Date Title
CN105142649A (zh) 造影剂配制品与有关制备方法
JP5985523B2 (ja) 造影剤の薬学的製剤を調製する方法
US11110185B2 (en) Combination formulation
JPH04500964A (ja) キレート組成物
US12303573B2 (en) Formulation of contrast media and process of preparation thereof
JPH04154729A (ja) 磁気共鳴造影剤
RU2815053C2 (ru) Состав контрастных средств и способ его получения
BR122025004748A2 (pt) Formulação farmacêutica líquida, tetraquelato derivado de do3a com quantidades sub-estequiométricas de íons gadolínio (gd3+), seu uso, e método de imagem do corpo inteiro de um indivíduo, ou de imagem de uma parte do corpo
HK40056424A (en) Formulation of contrast media and process of preparation thereof
BR112021007707B1 (pt) Formulação farmacêutica líquida, e seu processo de preparação

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151209